首页> The pharmacogenomics journal> Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients.

Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients.

导出 LinkOut

翻译打印收藏纠错

第一作者： F,Loupakis

第一单位： 1] U.O. Oncologia Medica 2 Universitaria, Azienda Ospedaliera-Universitaria Pisana, Pisa, Italy [2] Istituto Toscano Tumori (ITT), Firenze, Italy.

作者： F,Loupakis ^[1] ; C,Antoniotti ^[1] ; C,Cremolini ^[1] ; W,Zhang ^[2] ; D,Yang ^[2] ; T,Wakatsuki ^[2] ; P,Bohanes ^[2] ; M,Schirripa ^[1] ; L,Salvatore ^[1] ; G,Masi ^[1] ; V,Ricci ^[3] ; F,Graziano ^[4] ; A,Ruzzo ^[5] ; L,Benhaim ^[2] ; F,Marmorino ^[1] ; Y,Ning ^[2] ; R,El-Khoueiry ^[2] ; A,Falcone ^[1] ; H-J,Lenz ^[2]

作者单位： 1] U.O. Oncologia Medica 2 Universitaria, Azienda Ospedaliera-Universitaria Pisana, Pisa, Italy [2] Istituto Toscano Tumori (ITT), Firenze, Italy. ^[1] Department of Medical Oncology, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, USA. ^[2] Unità di Oncologia, Istituto Scientifico San Raffaele, Milano, Italy. ^[3] Medical Oncology Unit, Hospital of Pesaro, Pesaro, Italy. ^[4] Section of Biochemistry and Molecular Biology, Department of Biomolecular Sciences, University of Urbino, Urbino, Italy. ^[5]